Researcher profile

Ashkan Ertefaie

Ashkan Ertefaie contributes to research discovery and scholarly infrastructure.

ResearcherAffiliation not importedOpen to collaborate

Trust snapshot

Quick read

Trust 15 - UnverifiedVerification L1Unclaimed author
3works
0followers
3topics
4close collaborators

Actions

Decide how to stay connected

Follow researcher0

Identity and collaboration

How to connect with this researcher

Claiming links this public author record to a researcher profile and unlocks direct collaboration workflows.

Log in to claim

Direct collaboration

Open a focused conversation when the fit is right

Claim this author entity first to unlock direct invitations.

Research graph

See the researcher in context

Open full explorer

Inspect adjacent work, topics, institutions and collaborators without jumping out to a separate graph page.

Building this graph slice

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

3 published item(s)

preprint2020arXiv

Adjusting for Partial Compliance in SMARTs: a Bayesian Semiparametric Approach

The cyclical and heterogeneous nature of many substance use disorders highlights the need to adapt the type or the dose of treatment to accommodate the specific and changing needs of individuals. The Adaptive Treatment for Alcohol and Cocaine Dependence study (ENGAGE) is a multi-stage randomized trial that aimed to provide longitudinal data for constructing treatment strategies to improve patients' engagement in therapy. However, the high rate of noncompliance and lack of analytic tools to account for noncompliance have impeded researchers from using the data to achieve the main goal of the trial. We overcome this issue by defining our target parameter as the mean outcome under different treatment strategies for given potential compliance strata and propose a Bayesian semiparametric model to estimate this quantity. While it adds substantial complexities to the analysis, one important feature of our work is that we consider partial rather than binary compliance classes which is more relevant in longitudinal studies. We assess the performance of our method through comprehensive simulation studies. We illustrate its application on the ENGAGE study and demonstrate that the optimal treatment strategy depends on compliance strata.

preprint2020arXiv

Bayesian Set of Best Dynamic Treatment Regimes and Sample Size Determination for SMARTs with Binary Outcomes

One of the main goals of sequential, multiple assignment, randomized trials (SMART) is to find the most efficacious design embedded dynamic treatment regimes. The analysis method known as multiple comparisons with the best (MCB) allows comparison between dynamic treatment regimes and identification of a set of optimal regimes in the frequentist setting for continuous outcomes, thereby, directly addressing the main goal of a SMART. In this paper, we develop a Bayesian generalization to MCB for SMARTs with binary outcomes. Furthermore, we show how to choose the sample size so that the inferior embedded DTRs are screened out with a specified power. We compare log-odds between different DTRs using their exact distribution without relying on asymptotic normality in either the analysis or the power calculation. We conduct extensive simulation studies under two SMART designs and illustrate our method's application to the Adaptive Treatment for Alcohol and Cocaine Dependence (ENGAGE) trial.

preprint2020arXiv

Robust Q-learning

Q-learning is a regression-based approach that is widely used to formalize the development of an optimal dynamic treatment strategy. Finite dimensional working models are typically used to estimate certain nuisance parameters, and misspecification of these working models can result in residual confounding and/or efficiency loss. We propose a robust Q-learning approach which allows estimating such nuisance parameters using data-adaptive techniques. We study the asymptotic behavior of our estimators and provide simulation studies that highlight the need for and usefulness of the proposed method in practice. We use the data from the "Extending Treatment Effectiveness of Naltrexone" multi-stage randomized trial to illustrate our proposed methods.